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Abstract
The present study investigated a joint contribution of matrix metalloproteinases
(MMPs) genes to ischemic stroke (IS) development and analyzed interactions
between MMP genes and genome‐wide associated loci for IS. A total of 1288
unrelated Russians (600 IS patients and 688 healthy individuals) from Central
Russia were recruited for the study. Genotyping of seven single nucleotide
polymorphisms (SNPs) of MMP genes (rs1799750, rs243865, rs3025058,
rs11225395, rs17576, rs486055, and rs2276109) and eight genome‐wide
associated loci for IS were done using Taq‐Man–based assays and MALDI‐
TOF mass spectrometry iPLEX platform, respectively. Allele − 799T at
rs11225395 of the MMP8 gene was significantly associated with a decreased
risk of IS after adjustment for sex and age (OR = 0.82; 95%CI, 0.70‐0.96;
P= 0.016). The model‐based multifactor dimensionality reduction method has
revealed 21 two‐order, 124 three‐order, and 474 four‐order gene‐gene (G×G)
interactions models meaningfully (Pperm < 0.05) associated with the IS risk. The
bioinformatic analysis enabled establishing the studied MMP gene polymorph-
isms possess a clear regulatory potential and may be targeted by gene regulatory
networks driving molecular and cellular pathways related to the pathogenesis of
IS. In conclusion, the present study was the first to identify an association
between polymorphism rs11225395 of the MMP8 gene and IS risk. The study
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findings also indicate that MMPs deserve special attention as a potential class of
genes influencing the multistep mechanisms of cerebrovascular disease
including atherosclerosis in cerebral arteries, acute cerebral artery occlusion
as well as the ischemic injury of the brain and its recovery.
KEYWORD S
gene regulatory networks., gene‐gene interactions, ischemic stroke, matrix metalloproteinases,
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1 | INTRODUCTION
Stroke is the third most common cause of death and
chronic disability in developed countries.1 An important
point is that the overall burden of stroke in terms of an
absolute number of people affected or remained disabled;
the disease has dramatically increased across the globe in
both men and women.1 Ischemic stroke (IS) (also known
as a cerebral infarction) is the most common type of
cerebrovascular disease that occurs as a result of an
obstruction of the artery supplying blood to the brain.
Atherothrombotic stroke, a predominant type of IS,
occurs when a blood clot forms on an atherosclerotic
plaque within a cerebral artery.
Numerous studies demonstrated that genetic factors
play an essential role in the development of IS. In the vast
majority of cases, IS is a polygenic multifactorial disorder
resulting from complex interactions between genetic and
environmental factors which are jointly involved in the
disease development.2,3 Candidate gene and genome‐
wide association studies (GWAS) have identified a broad
spectrum of polymorphic genes whose effects on the
susceptibility to IS are mediated through abnormalities in
homocysteine metabolism, renin‐angiotensin‐aldosterone
system, hemostatic system, leukotriene metabolism and
other pathways.2 In recent years, there has been
increased interest in the study of matrix metalloprotei-
nases (MMPs) and their relation to pathogenesis of
cerebrovascular disease and brain recovery after IS.4-6
MMPs represent a group of proteolytic zinc‐dependent
enzymes synthesized by endothelial cells, neurons, glial
cells, and astrocytes and responsible for the collagen and
other protein degradation in extracellular matrix and
implicated in various pathological conditions such as
inflammation, tissue destruction, atherosclerosis, and
many other processes playing a role in diseases of the
central nervous system.4,7,8 An increased activity of
MMPs has been shown to be linked with the suscept-
ibility and severity of IS whereas a blockage in the activity
of MMPs was found to reduce disease risk or brain injury
after stroke.9 Thus, polymorphic genes encoding MMPs
become attractive candidates for serving as molecular
markers for susceptibility and clinical course of IS.
Almost three dozens of studies have been conducted to
assess associations between polymorphisms of genes
encoding individual MMPs and the risk of IS.6,10
However, these studies have been designed on popula-
tions with a small sample size that decreased the power
to detect genotype‐phenotype associations and, therefore,
yielded inconsistent and/or inconclusive results. A recent
systematic review and meta‐analysis of the 29 studies
investigated association between single nucleotide
polymorphisms (SNP) in MMP family genes and risk
of IS has shown that SNPs − 1562C/T of MMP9 and
− 1082A/G of MMP12 could be considered as risk factors
for IS, whereas polymorphisms −1607 1G/2G of MMP1,
− 1306C/T and − 735C/T of MMP2 and also −1612
5A/6A of MMP3 are not associated with disease risk.10
No studies so far have been done to evaluate a join
contribution of various MMPs to the development of IS
on populations with greater sample size than investigated
before. Therefore, the present study was designed (1) to
investigate a joint contribution of MMPs genes to IS
development; (2) to analyze interactions between genes
encoding MMPs and well‐known candidate genes for IS
susceptibility, and (3) to perform a comprehensive
bioinformatic analysis with a purpose to identify both
the regulatory potential of SNPs related to disease risk
and functional partners and regulators of MMPs involved
in different steps of pathogenesis of IS.
2 | MATERIALS AND METHODS
2.1 | Study participants
Ethical Review Committee of Kursk State Medical
University has approved study protocol. All participants
gave written informed consent before enrollment for this
study. A total of 1288 unrelated Russians (600 patients
with IS and 688 healthy individuals) from Central Russia
were recruited for the study. The patients were enrolled
from the Regional Cardiovascular Centre of Kursk
Regional Clinical Hospital and Neurology Division of
Kursk Emergency Hospital during two periods, between
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2007 and 2013 as described previously,11-13 and between
2015 and 2017. All patients were examined by qualiﬁed
neurologists. The diagnosis of cerebral infarction was
based on the results of the neurological examination and
computed tomography and/or magnetic resonance ima-
ging of the brain. Stroke patients with a history of cardiac
arrhythmias were not included in the study. To be
eligible, the subjects for the control group were required
to be in good health. This group was recruited from the
same population and for the same time periods and
included healthy blood volunteers and hospital‐based
patients with no clinical evidence for cerebrovascular,
cardiovascular, or other chronic diseases. Baseline and
clinical characteristics of the study population are listed
in Table 1. The control group was matched to the IS
group for sex, age and body mass index (P> 0.05).
2.2 | DNA analysis
Whole blood samples (5mL) were collected from all study
participants into EDTA‐coated tubes and maintained at
− 20°C until processed. Genomic DNA was isolated using
the standard procedure of phenol/chloroform extraction.
We have selected seven common frequently investigated
SNPs of MMP genes, namely −1607 2G/1G (rs1799750)
MMP1, − 1306C> T (rs243865) MMP2, −1612 5A/6A
(rs3025058)MMP3, − 799C>T (rs11225395) MMP8, c.836
A>G (rs17576) MMP9, c.158C> T (rs486055) MMP10,
and − 82A>G (rs2276109) MMP12. Genotyping of the
SNPs was done using Taq‐Man–based real‐time polymer-
ase chain reaction assays according to the protocols
published in the literature. Primer and probe sequences
are shown in Table S1. The polymerase chain reaction was
performed on the CFX96 Touch Real‐Time PCR Detection
System (Bio‐Rad Laboratories, Hercules, CA). In addition,
we have selected eight SNPs which have been found to be
strongly associated with IS risk in European GWAS. These
GWAS loci included rs2417957 of SLCO1B1,14 rs6511720
of LDLR,15 rs4322086 of RASEF,16 rs12449964 of PEMT,17
rs12646447 of PITX2,18 rs899997 of LOC105370913,17
rs11556924 of ZC3HC1,17 and rs783396 of AIM1.19
Genotyping of these genes was performed using a
MALDI‐TOF mass spectrometry iPLEX platform (Agena
Bioscience Inc, San Diego, CA). Primer sequences used for
genotyping are shown in Table S2. Blind replicates were
included to ensure quality control of genotyping. Labora-
tory personnel conducting genotyping were blinded to
patients’ information. The repeatability test was conducted
for 5% of randomly selected samples, yielded 100%
reproducibility. All molecular genetic investigations were
performed at the Research Institute of Genetic and
Molecular Epidemiology of Kursk State Medical Univer-
sity (Kursk, Russia).
2.3 | Statistical and bioinformatic
analysis
Allele frequencies were estimated by the gene counting
method. The χ2‐test was used to identify significant
departures from Hardy‐Weinberg equilibrium. P value
≤ 0.05 was considered statistically significant. Allele and
genotype frequencies in the study groups were analyzed
using the SNPStats software (http://bioinfo.iconcologia.
net/snpstats/start.htm).20 Associations between MMPs
genotypes and the risk of IS were evaluated by multiple
logistic regression assuming codominant, dominant,
recessive, overdominant and log‐additive genetic models
and adjusted for covariates such as age and gender. AIC
value (Akaike’s Information Criterion) was used to select
the best genetic model for SNP‐disease association.
A joint contribution of genes to the risk of IS was
evaluated by method multifactor dimensionality reduction
(MDR), a data‐mining and model‐free bioinformatic
approach to identifying high‐order gene‐gene and gene‐
environment interactions determining susceptibility to
complex multifactorial disorders.21,22 In the present study,
TABLE 1 Baseline and clinical characteristics of the study population
Baseline and clinical characteristics Controls (N= 688) IS patients (N= 600) P value
Age, M ± SD 60.8±7.5 61.1±9.8 0.59
Sex, N (%)
Males 366 (53.2) 330 (55.0) 0.52
Females 322 (46.8) 270 (45.0)
BMI (kg/m2), M ± SD 24.6 ± 3.8 25.2 ± 4.2 0.11
Hypertension 0 (0.0) 586 (97.7) ‐
Coronary artery disease 0 (0.0) 49 (8.2) ‐
Diabetes mellitus 0 (0.0) 52 (8.7) ‐
Abbreviations: BMI, body mass index; M, mean; N, number; SD, standard deviation.
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we utilized the model‐based multifactor dimensionality
reduction method (MB‐MDR), an extension of the MDR
method, which measures the association between multi‐
locus genotypes and the phenotype, providing a set of
statistically significant interactions instead of a single best
model.23 The mbmdr package for R was used to perform
modeling gene‐gene interactions underlying stroke sus-
ceptibility.24 A detailed algorithm of the usage of MB‐MDR
method was described previously.25 We evaluated two‐,
three‐, and four‐order gene‐gene interactions associated
with IS risk, and statistical significance (Pperm) for each n‐
order model was evaluated through 1000 permutation
tests.
The regulatory potential of SNPs of MMP genes was
evaluated in silico using two bioinformatics tools: (1) the
SNP Function Prediction (FuncPred) utilizing the TRANS-
FAC database of potential transcription factor (TF
recognition sites and available online at https://snpinfo.
niehs.nih.gov/snpinfo/snpfunc.html;26 (2) the rSNPBase
database of curated regulatory SNPs available at http://
rsnp.psych.ac.cn.27 Those transcription factor binding sites
falling into the investigated SNPs and whose core or
matrix match scores were impacted, or which were
eliminated or created by variant sequences are considered
to be regulatory within a particular SNP. Thus, the
FuncPred tool enabled identification transcription factors
binding sites (TFBS) and other regulatory proteins at SNP
regions, thereby gaining important information on the
gene regulatory networks having the potential to influence
expression and/or activity of the MMP genes.
To better understand the mechanisms by which
MMPs are involved in the polygenic basis of IS, we
performed an in silico search for biological processes,
molecular functions, and metabolic pathways up or
downregulating the functions of MMPs through the
binding with TFBS at their SNPs and potentially related
with disease pathogenesis. To accomplish this purpose,
enrichment analysis on a gene set was performed using
online tool hosted by Gene Ontology (GO, www.
geneontology.org). The enrichment analysis enabled
finding GO terms which are over‐represented (or under-
represented) using annotations for a gene set including
TFBS identified in the studied MMPs. To overcome the
multiple hypothesis testing issue, significance levels for
GO terms sharing with a gene set were evaluated by the
false discovery rate (FDR) and calculation of Q‐values,
which is the expected proportion of true null hypotheses
rejected out of the total number of null hypotheses
rejected28
Bioinformatic tool of the STRING Database v10.5
database (https://string‐db.org/)29 was used for visualiza-
tion of complex protein‐protein interactions between the
disease‐associated MMPs, their functional partners, gene
regulatory networks, and metabolic pathways which
could be involved in the molecular mechanisms of IS.
3 | RESULTS
3.1 | Allele and genotype frequencies of
MMPs SNPs: Interpopulation differences
and relationship with IS risk
The genotype and allele frequencies of matrix metallo-
proteinases SNPs are shown in Tables 1 and 2. The
observed genotype frequency for polymorphisms
rs1799750 of MMP1, rs243865 of MMP2, rs3025058 of
MMP3, rs486055 of MMP10 and rs2276109 of MMP12
were in Hardy‐Weinberg equilibrium (P> 0.05). A
deviation from Hardy‐Weinberg equilibrium was found
for SNPs rs11225395 of MMP8 and rs17576 of MMP9 due
to decreased values of observed heterozygosity (0.385 and
0.254, respectively), as compared with expected hetero-
zygosity values (0.480 and 0.295, respectively). Minor
allele frequencies (MAF) for SNPs rs1799750 of MMP1,
rs243865 of MMP2, rs3025058 of MMP3 and rs11225395
of MMP8 were in accordance with those reported in
European populations (www.ensembl.org), according to
the data published in 1000 Genomes Project, Phase 3.
Meantime, MAF for SNPs rs17576 of MMP9, rs486055 of
MMP10 and rs2276109 of MMP12 differed significantly
(P< 0.05) from those reported in Europeans. For
instance, MAF for SNP rs17576 of the MMP9 gene was
0.18 in our Russian population and 0.38 in Europeans.
Notably, a relatively low MAF for this SNP also occurs in
Peruvians from Lima (0.14), Mexicans from California
(0.27), Colombians from Medellin (0.26), Puerto Ricans
(0.25), and Gambians from the Western Division (0.27).
MAF for SNPs rs486055 of MMP10 and rs2276109 of
MMP12 in Russians were compatible with those reported
in European populations (0.17 vs 0.14 and 0.15 vs 0.12,
respectively).
The association analysis between polymorphic genes
encoding MMPs and the risk of IS is shown in Table 2.
Allele − 799T at rs11225395 of the MMP8 gene was
significantly associated with decreased risk of IS after
adjustment for sex and age (OR = 0.82; 95%CI, 0.70‐0.96;
P= 0.016). As can be seen from Table 2, no statistically
significant associations between the MMPs genotypes
and IS risk were found (P> 0.05). Then we performed a
replication study of eight genome‐wide associated loci for
IS established in European populations (Table 3). We
found that allele G (OR= 1.29; 95%CI, 1.10‐1.51;
P= 0.002) and genotype A/G (OR= 1.44; 95%CI, 1.03‐
2.03; P< 0.0001) for SNP rs4322086 of the RASEF gene
were significantly associated with increased risk of IS.
Furthermore, the C/T genotype of ZC3HC1 (SNP
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rs11556924) was significantly associated with increased
risk of IS (OR= 1.38; 95%CI, 1.08‐1.77; P= 0.037). No
significant associations were found between other
genome‐wide associated loci and disease risk (P> 0.05).
Thus, the present study was able to validate two of eight
investigated SNPs such as rs4322086 of RASEF and of
rs11556924 of ZC3HC1 as IS susceptibility loci in the
Russian population.
3.2 | High‐order interactions between
the studied genes and the risk of IS
The MB‐MDR method was applied to the data set aiming
to identify whether epistatic interactions between poly-
morphic genes for MMPs and genome‐wide associated loci
for IS jointly contribute to the disease risk. Totally, 21 two‐
order, 124 three‐order, and 474 four‐order gene‐gene
(G×G) interactions models showed significant associations
(Pperm < 0.05) with the risk of IS (a detailed description of
all gene‐gene models are presented in Tables S3‐S5).
Notably, 14 of 21 two‐order models (67%), 104 of 124
three‐order models (84%), and 445 of 474 four‐order (94%)
comprised MMP genes interacting to each other or to the
IS loci identified by GWAS. Table 4 summarizes the best
n‐order G×G interactions models underlying susceptibility
to IS (only the top 4 G×G models per an order are shown
in Table 4). The best two‐order G×G models comprised
interactions between gene polymorphisms such as
rs3025058 of MMP3, rs11225395 of ММР8, rs17576 of
MMP9, rs4322086 of RASEF, and rs11556924 of ZC3HC1
(Pperm< 0.001). SNPs rs11225395 of ММР8, rs1799750 of
MMP1, rs243865 of MMP2 or rs3025058 of MMP3 were
presented in each of the four three‐order G×G models in
combinations with the GWAS loci such as rs4322086 of
RASEF, rs11556924 of ZC3HC1, rs899997 of SLCO1B1,
and rs12449964 of PEMT (Pperm< 0.002). Furthermore,
each of the best three four‐order G×G interactions shown
in Table 4, included at least two genes for MMPs such as
rs3025058 of MMP3, rs11225395 of ММР8, rs1799750 of
MMP1, or rs17576 of MMP9 in combinations with
genome‐wide associated loci for IS such as rs4322086 of
RASEF, rs11556924 of ZC3HC1, rs899997 of SLCO1B1, or
rs12449964 of PEMT (Pperm< 0.005).
3.3 | Bioinformatic analysis for the
regulatory potential of MMP SNPs
Table 5 summarizes the results of an in silico analysis for
the regulatory potential of SNPs of MMP genes using two
bioinformatic tools such as FuncPred (https://snpinfo.
TABLE 2 Association analysis between polymorphic genes for matrix metalloproteinases and the risk of ischemic stroke
Genes (SNP ID) Genotype, allele
N (%)
P value corOR (95% CI)Controls (N= 688) IS patients (N= 600)
MMP1‐1607 2G/1G (rs1799750) 1G/1G 172 (25.3) 159 (26.5) 0.79 1.00
1G/2G 345 (50.7) 305 (50.8) 0.96 (0.73‐1.25)
2G/2G 164 (24.1) 136 (22.7) 0.90 (0.66‐1.23)
1G 0.506 0.519 0.50 1.05 (0.90‐1.29)
MMP2 ‐1306C > T (rs243865) C/C 401 (59.9) 366 (61.6) 0.43 1.00
C/T 224 (33.4) 198 (33.3) 0.97 (0.76‐1.22)
T/T 45 (6.7) 30 (5.0) 0.73 (0.45‐1.18)
T 0.234 0.247 0.30 0.91 (0.75‐1.09)
MMP3 ‐1612 5A/6A (rs3025058) 6A/6A 186 (27.5) 172 (28.7) 0.61 1.00
5A/6A 349 (51.5) 293 (48.8) 0.91 (0.70‐1.17)
5A/5A 142 (21.0) 135 (22.5) 1.02 (0.75‐1.40)
5A 0.469 0.468 0.93 1.01 (0.86‐1.18)
MMP8 ‐799C > T (rs11225395) C/C 251 (38) 261 (43.9) 0.076 1.00
C/T 261 (39.5) 222 (37.3) 0.82 (0.64‐1.05)
T/T 148 (22.4) 112 (18.8) 0.72 (0.54‐0.98)
T 0.422 0.375 0.016 0.82 (0.70‐0.96)
MMP9 c.836A >G (rs17576) A/A 477 (70.3) 404 (68.1) 0.055 1.00
A/G 158 (23.3) 165 (27.8) 1.23 (0.95‐1.59)
G/G 43 (6.3) 24 (4.0) 0.66 (0.40‐1.11)
G 0.180 0.180 0.98 1.00 (0.81‐1.22)
MMP10 c.158C > T (rs486055) C/C 456 (67.7) 415 (69.2) 0.24 1.00
C/T 191 (28.3) 171 (28.5) 0.98 (0.77‐1.26)
T/T 27 (4.0) 14 (2.3) 0.57 (0.30‐1.11)
T 0.182 0.166 0.29 0.90 (0.73‐1.10)
MMP12 ‐82A>G (rs2276109) A/A 507 (74.9) 419 (69.8) 0.11 1.00
A/G 155 (22.9) 168 (28.0) 1.31 (1.02‐1.69)
G/G 15 (2.2) 13 (2.2) 1.04 (0.49‐2.21)
G 0.137 0.162 0.076 1.22 (0.98‐1.52)
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niehs.nih.gov/snpinfo/snpfunc.php) and rSNPBase data-
base (http://rsnp.psych.ac.cn). We revealed that poly-
morphisms rs243865 ofMMP2, rs11225395 ofMMP8, and
rs2276109 of MMP12 are located within binding sites for
multiple transcription factors. Detailed information on
TFBS is shown in Tables S6 to S8). In particular, intronic
polymorphism − 1306C > T (rs243865) of theMMP2 gene
(Table S6) contains a functional motif related to the
regulatory effects of numerous TFBS such as ZEB1, AR,
ATF6, CACD, VDR, TEAD2, NR3C1, HAND1, ZNF354C,
NF1, NKX2‐5, PAX6, PAX8, PLZF, SP3, SPZ1, SCAP,
SCAP, TBX5, VDR, WT1, and ZBTB14. As shown in
Table S7, an intronic SNP − 799C > T (rs11225395) of the
MMP8 gene is located within binding sites for transcrip-
tion factors such as TFAP2A, CUTL1, CRX, DBP, RXRB,
NR3C1, HAND1, HNF4A, NF1, POU2F1, POU3F1,
PAX5, PAX6, PAX8, PLZF, POU3F2, POU6F1, PPARA,
PPARG, RFX1, TBP, and VDR. As can be seen from Table
S8, a SNP rs2276109 in the promoter of the MMP12 gene
falls into a recognition site for multiple TFBS such as
JUN, ZEB1, BACH2, BRCA1, CUX1, CUX1, CEBPG,
ESR1, NR1H4, FOXQ1, MAF, HOXA9, MYB, MYOD1,
NKX2‐5, POU2F1, PAX2, PAX3, PAX5, and PAX6. Thus,
polymorphisms rs243865 ofMMP2, rs11225395 ofMMP8,
and rs2276109 of MMP12 are located within functional
motifs shared with multiple signaling pathways and
driven by gene regulatory networks.
Additionally, many SNPs were found to possess own
regulatory potential, as predicted by the FuncPred tool, or
are in linkage disequilibrium with known regulatory SNPs
(Table 4). It should be noted that almost all investigated
MMPs polymorphisms (except of rs3025058 of MMP3) are
involved in proximal regulation of the promoter activity of
corresponding genes (Tables S9‐S15). Moreover, two coding
SNPs such as rs17576 of MMP9 and rs486055 of MMP10
represent the targets for posttranscriptional regulation of
gene expression and/or activity through an RNA‐binding
protein mechanism (Table S15). Interestingly, several SNPs
represent subjects to epigenetic modifications influencing
gene activity in various cell types and tissues. In particular,
TABLE 3 SNPs associated with ischemic stroke in genome‐wide association studies in European populations: a replication study in
population from the Central Russia
Genes (SNP ID) Genotype, allele
N (%)
P value corOR (95% CI)Controls (N= 688) IS patients (N= 600)
ZC3HC1 (rs11556924) C/C 280 (44.0) 195 (37.1) 0.037 1.00
C/T 281 (44.2) 270 (51.4) 1.38 (1.08‐1.77)
T/T 75 (11.8) 60 (11.4) 1.16 (0.79‐1.70)
T 0.339 0.371 0.10 1.15 (0.97‐1.37)
PEMT (rs12449964) C/C 251 (37.2) 221 (38.9) 0.75 1.00
C/T 336 (49.8) 279 (49.1) 0.95 (0.74‐1.20)
T/T 88 (13.0) 68 (12.0) 0.87 (0.61‐1.26)
T 0.379 0.365 0.47 0.94 (0.80‐1.11)
PITX2 (rs12646447) T/T 424 (78.7) 332 (79) 0.50 1.00
T/C 100 (18.6) 71 (16.9) 0.91 (0.65‐1.28)
C/C 15 (2.8) 17 (4.0) 1.43 (0.70‐2.91)
C 0.121 0.125 0.77 1.04 (0.79‐1.37)
SLCO1B1 (rs2417957) C/C 564 (98.8) 556 (98.1) 0.37 1.00
C/T 7 (1.2) 10 (1.8) 1.54 (0.58‐4.09)
T/T 0 (0.0) 1 (0.2) ‐
T 0.006 0.011 0.35 1.69 (0.68‐4.18)
RASEF (rs4322086) A/A 260 (39.8) 162 (27.9) < 0.0001 1.00
A/G 288 (44.0) 323 (55.6) 1.81 (1.41‐2.33)
G/G 106 (16.2) 96 (16.5) 1.44 (1.03‐2.03)
G 0.382 0.443 0.002 1.29 (1.10‐1.51)
LDLR (rs6511720) G/G 606 (95.0) 520 (93.9) 0.57 1.00
G/T 30 (4.7) 33 (6.0) 1.28 (0.77‐2.13)
T/T 2 (0.3) 1 (0.2) 0.58 (0.05‐6.37)
T 0.027 0.032 0.47 1.19 (0.74‐1.92)
AIM1 (rs783396) C/C 603 (91.8) 518 (90.1) 0.16 1.00
C/A 54 (8.2) 55 (9.6) 1.18 (0.79‐1.75)
A/A 0 (0.0) 2 (0.4) ‐
A 0.041 0.051 0.28 1.26 (0.86‐1.84)
LOC105370913 (rs899997) T/T 327 (51.9) 302 (56.3) 0.23 1.00
T/G 253 (40.2) 190 (35.5) 0.81 (0.63‐1.03)
G/G 50 (7.9) 44 (8.2) 0.96 (0.62‐1.49)
G 0.280 0.259 0.26 0.90 (0.75‐1.08)
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various histone marked regions have been found to be
associated with polymorphisms such as rs1799750 of
MMP1, rs243865 of MMP2, rs11225395 of MMP8, rs17576
of MMP9, rs486055 of MMP10, and rs2276109 of MMP12
(Tables S9‐S15). We also found that polymorphism rs17576
of the MMP9 gene spans the region of an exon splice
enhancer pointing out that the motif represents a critical site
for tissue‐specific regulation of gene expression (Table S16).
SNPs such as rs243865 of MMP2, rs11225395 of MMP8,
rs17576 of MMP9, and rs2276109 of MMP12 represent
expression quantitative trait loci (eQTLs), i.e genomic loci
explaining all or a fraction of variation in expression levels of
mRNAs.30 For instance, meaningful eQTLs were found for
SNP rs11225395 in whole blood (P=4.8 × 10−9), skeletal
muscle (P=0.0000092), subcutaneous adipose tissue
(P=1.1 × 10−8), and also in skin exposed (P=2.4 × 10−10)
and not exposed to sun (P=0.0000022) (Data of GTEx
portal, v7, https://gtexportal.org).
3.4 | In silico search for potential
regulators of MMPs and biological
processes related to their effects
GO enrichment analysis on a gene set including
transcription factors targeting SNPs of MMPs such
as rs11225395 of MMP8, rs243865 of MMP2, and
rs2276109 of MMP12 (Tables S6‐S8) enabled identifica-
tion of biological processes, molecular functions and
metabolic pathways that could up or down‐regulate the
functions of the MMPs. Table S17 shows biological
processes related to the functions of the given MMPs.
Biological processes and metabolic pathways that may
play roles in the pathogenesis of IS were of great
interest. In particular, the following GO terms related
to the regulation of lipid metabolism and atherosclero-
sis formation were identified for a gene set including
TF binding to an SNP rs11225395 of MMP8: regulation
of sequestering of triglyceride (GO:0010889, Q = 0.01),
negative regulation of sequestering of triglyceride
(GO:0010891, Q= 0.003), regulation of cholesterol
storage (GO:0010885, Q= 0.01), negative regulation
of cholesterol storage (GO:0010887, Q = 0.005), regula-
tion of fatty acid oxidation (GO:0046320, Q = 0.02),
positive regulation of fatty acid oxidation (GO:0046321,
Q= 0.01), negative regulation of lipid storage
(GO:0010888, Q = 0.02), regulation of lipid metabolic
process (GO:0019216, Q = 0.05), regulation of macro-
phage derived foam cell differentiation (GO:0010743,
Q= 0.04), and negative regulation of macrophage
derived foam cell differentiation (GO:0010745,
Q= 0.01). GO terms related with apoptosis playing
a role in neuronal cell death included: positive
TABLE 4 The best gene‐gene (G×G) interactions significantly associated with the risk of ischemic stroke
Genes and SNPs in interactions NH β H WH NL β L WL Pperm
Two‐order G×G interactions
1 MMP3 rs3025058 × RASEF rs4322086 2 0.113 13.17 3 −0.182 34.54 < 0.001
2 MMP9 rs17576 × RASEF rs4322086 3 0.160 31.96 2 −0.145 20.25 < 0.001
3 RASEF rs4322086 × ZC3HC1 rs11556924 1 0.183 26.66 2 −0.123 14.73 < 0.001
4 ММР8 rs11225395 × ZC3HC1 rs11556924 2 0.173 25.79 2 −0.119 7.47 < 0.001
Three‐order G×G interactions
1 ММР8 rs11225395 × RASEF rs4322086 × ZC3HC1 rs11556924 4 0.253 43.39 4 −0.185 18.20 < 0.002
2 MMP1 rs1799750 × SLCO1B1 rs899997 × RASEF rs4322086 3 0.221 38.21 4 −0.177 28.32 < 0.002
3 MMP2 rs243865 × RASEF rs4322086 × ZC3HC1 rs11556924 4 0.206 37.42 4 −0.163 24.65 < 0.002
4 MMP3 rs3025058 × RASEF rs4322086 × PEMT rs12449964 2 0.252 14.24 6 −0.206 37.39 < 0.002
Four‐order G×G interactions
1 MMP3 rs3025058 ×ММР8 rs11225395 × RASEF rs4322086 × ZC3HC1
rs11556924
9 0.366 66.04 7 −0.329 43.20 < 0.005
2 MMP1 rs1799750 ×MMP9 rs17576 × SLCO1B1 rs899997 × RASEF rs4322086 7 0.280 58.04 6 −0.233 32.89 < 0.005
3 MMP3 rs3025058 ×ММР8 rs11225395 × RASEF rs4322086 × PEMT rs12449964 9 0.301 57.70 10 −0.290 50.46 < 0.005
4 ММР8 rs11225395 × LDLR rs6511720 × RASEF rs4322086 × ZC3HC1
rs11556924
6 0.283 55.90 6 −0.192 22.43 < 0.005
Abbreviations: βH, regression coefficient for high‐risk exposition in the step 2 analysis; βL, regression coefficient for low‐risk exposition in the step 2 analysis;
NH, number of significant high‐risk genotypes in the interaction; NL, number of significant low‐risk genotypes in the interaction; WH, Wald statistic for the
high‐risk category; WL, Wald statistic for the low‐risk category.
Models are obtained using the model‐based multifactor dimensionality reduction method, MB‐MDR package for R.
Pperm, permutation P value for the interaction model. The models were adjusted for age and sex.
The full list of statistically significant models for gene‐gene interactions is presented in Tables S3‐S5.
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regulation of apoptotic process (GO:0043065,
Q = 0.04), positive regulation of programmed cell death
(GO:0043068, Q = 0.04) and positive regulation of cell
death (GO:0010942, Q = 0.05). GO terms related to
biological processes participating in ischemic injury
of the brain and its recovery after stroke included:
negative regulation of neural precursor cell prolifera-
tion (GO:2000178, Q= 0.02), regulation of neuroblast
proliferation (GO:1902692, Q=0.04), astrocyte develop-
ment (GO:0014002, Q= 0.04), astrocyte differentiation
(GO:0048708, Q=0.003), regulation of oligodendrocyte
differentiation (GO:0048713, Q=0.05), glial cell develop-
ment (GO:0021782, Q= 0.01), myelination (GO:0042552,
Q= 0.02), glial cell differentiation (GO:0010001, Q= 0.003),
gliogenesis (GO:0042063, Q= 0.008), cerebral cortex
development (GO:0021987, Q= 0.001), ensheathment of
neurons (GO:0007272, Q= 0.02), axon ensheathment
(GO:0008366, Q=0.02), central nervous system develop-
ment (GO:0007417, Q= 0.00006), and brain development
(GO:0007420, Q=0.01).
For a gene set including TFBS at SNP rs243865 of
MMP2, we identified GO terms related to a development
of the cardiovascular system and regulation of apoptosis:
vasculogenesis (GO:0001570, Q= 0.0001), blood vessel
development (GO:0001568, Q= 0.0000002), vasculature
development (GO:0001944, Q= 0.0000002), blood vessel
morphogenesis (GO:0048514, Q= 0.00001), cardiovascu-
lar system development (GO:0072358, Q= 0.0000003),
regulation of apoptotic process (GO:0042981, Q= 0.001),
positive regulation of apoptotic process (GO:0043065,
Q= 0.02), regulation of programmed cell death
(GO:0043067, Q= 0.001), positive regulation of pro-
grammed cell death (GO:0043068, Q= 0.02), regulation
of cell death (GO:0010941, Q= 0.0002), positive regula-
tion of cell death (GO:0010942, Q= 0.02), and negative
regulation of cell death (GO:0060548, Q= 0.02).
GO terms related with the development of nervous
system and processes playing a role in stroke pathogen-
esis such as apoptosis and oxidative stress were identified
for a gene set including TFBS at SNP rs2276109 of
MMP12: nervous system development (GO:0007399,
Q= 0.008), regulation of nervous system development
(GO:0051960, Q= 0.009), positive regulation of nervous
system development (GO:0051962, Q= 0.04), neurogen-
esis (GO:0022008, Q = 0.03), regulation of neurogenesis
(GO:0050767, Q= 0.04), positive regulation of neurogen-
esis (GO:0050769, Q= 0.004), regulation of cell death
(GO:0010941, Q= 0.04), regulation of apoptotic process
(GO:0042981, Q= 0.03), regulation of programmed cell
death (GO:0043067, Q= 0.03), cellular response to
reactive oxygen species (GO:0034614, Q= 0.02), and
regulation of reactive oxygen species metabolic process
(GO:2000377, Q= 0.04).
3.5 | Bioinformatic analysis for
functional partners of MMPs involved
in the molecular basis of IS
An important objective of the present study was to
analyze molecular interactions between MMPs, metabolic
pathways, and gene regulatory networks potentially
involved in the pathogenesis of IS. The bioinformatic tool
of the STRING database enabled identification protein‐
protein interactions between MMPs associated with IS in
our study and their functional partners in the form of
interactome network representing the structural, spatial,
and functional conjugation of MMPs with other protein
components of the network (Figure 1). The structure of an
interactome network indicates that the interacting pro-
teins are at least a biologically related group of
molecules.29 The present interactome network included
176 protein‐protein interactions (PPI) comprising mean-
ingful interactions between 25 proteins at PPI enrichment
P value= 1.0 × 10−16. As indicated in Figure 1, the 10
functional partners that are most tightly interacting with
IS‐related MMPs represent a core part of the interactome
network. These functional partners included: TIMP
metallopeptidase inhibitors such as type 1 (TIMP1, Gene
ID: 7076, OMIM: 305370), type 2 (TIMP2, Gene ID: 7077,
OMIM: 188825), and type 3 (TIMP3, Gene ID: 7078,
OMIM: 188826), plasminogen (PLG, Gene ID: 5340,
OMIM: 173350), Jun proto‐oncogene (JUN, Gene ID:
3725, OMIM: 165160), CD44 molecule (CD44, Gene ID:
960, OMIM: 107269), vascular endothelial growth factor A
(VEGFA, Gene ID: 7422, OMIM: 192240), basigin or Ok
blood group (BSG, Gene ID: 682, OMIM: 109480), nuclear
factor kappa B subunit 1 (NFKB1, Gene ID: 4790, OMIM:
164011), and tumor protein p53 (TP53, Gene ID: 7157,
OMIM: 191170). GO enrichment analysis performed by
bioinformatic tools of the STRING database enabled
identification of GO biological processes terms associated
with IS‐related MMPs (Table S17), their molecular
functions and cellular components (Table S18) as well
as the KEGG Pathways (Table S19) in which the MMPs
are potentially involved.
Finally, biological processes reflecting the functions
of MMPs and related with pathogenesis of IS were
selected from the GO list (GO terms listed below are
ranked by descending a degree of involvement of the
MMPs in the biological processes): extracellular matrix
disassembly (GO:0022617, Q= 5 × 10−15), collagen cata-
bolic process (GO:0030574, Q= 1 × 10−7), response to
oxidative stress (GO:0006979, Q= 1 × 10−6), regulation
of proteolysis (GO:0030162, Q= 1 × 10−6), regulation of
response to stress (GO:0080134, Q= 2 × 10−6), regula-
tion of cell death (GO:0010941, Q= 3 × 10−6), response
to toxic substance (GO:0009636, Q= 6 × 10−6), cell
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FIGURE 1 Interactome network representing protein‐protein interactions between matrix metolloproteinases associated with the risk
of ischemic stroke and other proteins. Network nodes represent proteins: splice isoforms or posttranslational modifications are collapsed,
that is, each node represents all the proteins produced by a single, protein‐coding gene locus. Colored nodes: query proteins and first shell of
interactors; white nodes: second shell of interactors; empty nodes: proteins of unknown 3D structure; filled nodes: some 3D structure is
known or predicted. Edges represent protein‐protein associations: associations are meant to be specific and meaningful, that is, proteins
jointly contribute to a shared function; this does not necessarily mean they are physically binding each other
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migration (GO:0016477, Q= 1 × 10−5), response to
mechanical stimulus (GO:0009612, Q=2× 10−5), aging
(GO:0007568, Q=5× 10−5), angiogenesis (GO:0001525,
Q=0.0001), blood coagulation (GO:0007596, Q=0.0002),
positive regulation of cell death (GO:0010942, Q=0.0003),
regulation of cell migration (GO:0030334, Q=0.0003),
blood vessel morphogenesis (GO:0048514, Q=0.0003),
response to chemical (GO:0042221, Q=0.0006), blood
vessel development (GO:0001568, Q=0.0008), stress‐acti-
vated MAPK cascade (GO:0051403, Q=0.0008), response to
hypoxia (GO:0001666, Q=0.0009), vasculature develop-
ment (GO:0001944, Q=0.001), proteolysis (GO:0006508,
Q=0.001), positive regulation of cell proliferation
(GO:0008284, Q=0.001), positive regulation of cell migra-
tion (GO:0030335, Q=0.002), regulation of cell‐substrate
adhesion (GO:0010810, Q=0.002), cellular response to
oxidative stress (GO:0034599, Q=0.002), regulation of
MAPK cascade (GO:0043408, Q=0.003), response to
reactive oxygen species (GO:0000302, Q=0.003), positive
regulation of neuron death (GO:1901216, Q=0.003),
positive regulation of apoptotic signaling pathway
(GO:2001235, Q=0.003), positive regulation of endothelial
cell proliferation (GO:0001938, Q=0.003), positive regula-
tion of MAPK cascade (GO:0043410, Q=0.005), inflamma-
tory response (GO:0006954, Q=0.005), regulation of
cellular response to stress (GO:0080135, Q=0.006), regula-
tion of cell proliferation (GO:0042127, Q=0.006), apoptotic
process (GO:0006915, Q=0.006), platelet degranulation
(GO:0002576, Q=0.007), positive regulation of macrophage
derived foam cell differentiation (GO:0010744, Q=0.007),
cellular response to reactive oxygen species (GO:0034614,
Q=0.007), cellular response to hypoxia (GO:0071456,
Q=0.01), positive regulation of apoptotic process
(GO:0043065, Q=0.01), regulation of cell adhesion
(GO:0030155, Q=0.01), regulation of reactive oxygen
species metabolic process (GO:2000377, Q=0.02), pro-
grammed necrotic cell death (GO:0097300, Q=0.02),
positive regulation of cytokine production (GO:0001819,
Q=0.02), regulation of apoptotic signaling pathway
(GO:2001233, Q=0.03), programmed cell death
(GO:0012501, Q=0.03), positive regulation of neuron
apoptotic process (GO:0043525, Q=0.04), and cellular
response to stress (GO:0033554, Q=0.05).
4 | DISCUSSION
4.1 | Joint contribution of MMP genes
to the pathogenesis of IS
To date, three dozens of association studies have been
conducted to elucidate associations of polymorphic genes
encoding MMPs with the risk of IS in various populations
of the world. Despite these studies have yielded incon-
sistent results, recent meta‐analysis10 enabled identifica-
tion two polymorphisms such as − 1562C/T of MMP9
and − 1082A/G of MMP12 as meaningful markers for IS
susceptibility. It is important to note, that all the studies
investigated associations between particular MMP genes
and IS risk have been conducted on populations with
small sample size, reducing the power to obtain reliable
estimates for genetic effects of MMPs on disease risk. The
present study is the first attempt to assess the joint
involvement of genes encoding various MMPs in the
multistep molecular mechanisms of cerebrovascular
disease on a large population of the Central Russia. The
present study demonstrated, for the first time, that MMPs
is an important class of genes collectively involved in
various stages of cerebrovascular disease, starting from
the formation of atherosclerosis in carotid arteries, their
occlusion to ischemic injury of the brain and its recovery
after stroke.
Our study was the first to identify an association
between polymorphism rs11225395 (− 799C > T) of the
MMP8 gene and IS risk. A recent study of Han et al31
conducted on mice has identified that MMP8 represents a
critical factor for brain damage in transient focal cerebral
ischemia via modulating neuroinflammation likely mi-
croglial activation and production of tumor necrosis
factor alpha. This means the rs11225395 polymorphism
of the MMP8 gene may be considered as a novel genetic
marker of susceptibility to IS however this association
should be confirmed by independent studies. The present
study has confirmed the results of meta‐analysis
27 studies10 that polymorphisms rs1799750 (−1607 2G/
1G) of MMP1, rs243865 (− 1306C > T) of MMP2 and
rs3025058 (−1612 5A/6A) of MMP3 are not associated
with the risk for IS. However a recent meta‐analysis
conducted by Zhang et al6 and including ethnically
diverse populations has observed that rs1799750 of
MMP1and also rs2276109 of MMP12 are associated with
the risk IS, although a relationship between the
polymorphisms and disease risk varied substantially
across different races. Clear tendencies in the relation-
ship between SNPs rs2276109 of MMP12 and rs17576 of
MMP9 with IS risk was also seen in our study, but
the association did not reach statistical significance.
In addition, our study has successfully confirmed
associations of polymorphisms rs4322086 of RASEF
and rs11556924 of ZC3HC1 with increased risk of IS,
SNPs originally established by GWAS in European
populations.16,17
It is well known that gene‐gene interaction (or
epistasis) is an important genetic mechanism underlying
susceptibility to complex polygenic disorders.32 Since
gene‐gene interaction represents the rule rather than
the exception for genes determining complex disease
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phenotypes like IS, the present study was also designed to
evaluate whether epistatic interactions between MMP
genes and the GWAS loci interact to each other to
produce the disease phenotype. We found that rs4322086
of RASEF and rs11556924 of ZC3HC1 and some other
GWAS loci interact tightly to MMP genes pointing out
that the genes are collectively involved in the molecular
basis of IS. The MB‐MDR enabled identification of
numerous high‐order gene‐gene interaction models,
associated with IS risk. Notably, a large portion of the
G×G interaction models comprised various MMP genes
pointing out that these genes are characterized by a
greater contribution to the polygenic mechanisms of IS
risk than disease susceptibility loci established by GWAS.
Although one‐way statistical analysis failed to show
associations of disease risk with a majority of the
investigated MMPs, the observed gene‐gene interactions
demonstrate a greater contribution of these genes to the
development of IS when they act in cooperation than
alone. To the best of our knowledge, this is the first study
reporting that complex interactions between MMP genes
and known disease susceptibility genes constitute the
molecular basis for the development of IS.
The involvement of MMPs in the complex pathophy-
siology of IS can be supported by numerous publications
in the literature.4,7-9 The GO enrichment analysis of a set
of transcription factors associated with MMP genes has
identified biological functions of MMPs that may play
roles in the development of IS. These functions include:
(1) angiogenesis and induction of cell proliferation in the
vascular wall; (2) increased cell migration and adhesion;
(3) destruction of the extracellular matrix around the
atherosclerotic plaque leading to its destabilization and
rupture; (4) activation of blood coagulation and intravas-
cular thrombus formation; (5) stimulation of vascular
inflammation; and (6) apoptosis of cells including
neurons. Based on the results of the GO enrichment
analysis and PubMed publications on biological functions
of MMPs, we summarized the potential mechanisms by
which MMPs are involved in the multistep pathogenesis
of the cerebrovascular disease (Figure 2). As indicated in
Figure 2, there are at least three stages of the develop-
ment of cerebrovascular disease in which MMPs are
involved: (1) atherosclerotic lesions of cerebral arteries,
(2) acute cerebral artery occlusion, and (3) ischemic
injury of the brain. First, MMPs is a part of molecular and
FIGURE 2 Pleiotropic effects of matrix metalloproteinases on multistep pathogenesis of the cerebrovascular disease. At least three
points of application for effects of matrix metalloproteinases (MMP1, MMP2, MMP3, MMP8, and MMP9 associated with the ischemic stroke
risk) to the pathogenesis of ischemic stroke are suggested: (1) the involvement in multiple stages of atherosclerosis of cerebral arteries; (2)
acute cerebral artery occlusion resulting from a rupture of instable atherosclerotic plaque and/or thrombosis of cerebral artery; (3) the
involvement in pathological processes during and after ischemic injury of the brain. Conclusions on the effects of these MMPs on the
pathogenesis of ischemic stroke are based on the bioinformatics analysis of Gene Ontology (GO) terms significantly associated with the gene
set (false discovery rate < 0.05). A detailed description of GO terms is present in the body of text
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cellular pathways driving the atherosclerotic process in
the vessels. In particular, MMPs are involved in the
formation and progression of the atherosclerotic process
through the positive regulation of biological functions
such as cell migration and proliferation (including
endothelial cells), differentiation of foam cells from
macrophages, MAPK cascade activation, enhanced gen-
eration of reactive oxygen species, cytokine production,
inflammation response, and angiogenesis of blood
vessels.7 Second, MMPs are known to be responsible for
both the rupture of unstable plaque and intraluminal
thrombus formation in the artery. Interestingly, MMPs
may be activated in response to an exposure to various
environmental stressors such as tobacco smoking and
drinking alcohol,33,34 well recognized etiological factors
of cerebrovascular disease. The activated enzymes are
known to be involved in the degradation of extracellular
matrix, activation of collagen catabolism, induction of
proteolysis, inflammation, platelet degranulation, and
plasminogen activation, the processes leading to the
destabilization and rupture of atherosclerotic plaque and
thrombosis of the cerebral artery.35-37 Finally, MMPs
mediate many biological and pathological processes
during and after ischemic injury of the brain. In
particular, MMPs participate in the regulation of many
processes in ischemic brain tissue such as induction of
neuronal apoptosis, activation of cytokine production and
inflammation, thereby influencing the severity of brain
damage, and activity of repairing the damaged tissue.38-40
Moreover, many functional partners of MMPs and their
coregulated transcription factors such as members of the
FOS and JUN gene families, that have been identified in
the present study by GO enrichment analysis, play a
crucial role in controlling the cell cycle, development,
growth, and cell differentiation in the central nervous
system, thereby demonstrating an importance of MMPs
in the regulation of recovery processes in brain tissues
after IS.
4.2 | MMP genes as targets for gene
regulatory networks
A comprehensive bioinformatic analysis enabled estab-
lishing that the studied MMP gene polymorphisms
possess a clear regulatory potential and may be targeted
by gene regulatory networks driving molecular and
cellular pathways related to the pathogenesis of the
cerebrovascular disease. For instance, we found that
several SNPs of MMP genes fall into a recognition site for
multiple transcription factors. TFBS are short sequences
on the DNA representing targets for transcription factors
driving and controlling gene expression and orchestrating
gene activity.41 In other words, transcription factors can
be considered as effector nodes affecting the behavior of
their downstream target genes, and a gene regulatory
network represents a collection of regulatory interactions
between transcription factors and their target genes.42
Polymorphisms of MMP genes (ie MMP8, MMP9,
MMP1, MMP2, and MMP3) which alone or in combina-
tion with other genes were found to be associated with
the risk of IS in our study represent a great interest, as
they give important information on how transcriptional
regulation of disease‐associated genes is organized at the
genome‐wide level. For instance, we found transcription
factors such as FOS and GATA‐2 and CEBPB to be
responsible for proximal regulation of activity/expression
of the MMP1 gene through the binding to an SNP
rs1799750. Interestingly, CEBPB is an important tran-
scription factor that binds to the promoter regions of
numerous genes involved in inflammatory processes,
synergistically enhancing and supporting their expression
in response to pro‐inflammatory stimulation.43 In addi-
tion, polymorphisms such as rs1799750 of MMP1,
rs243865 of MMP2, rs11225395 of MMP8, rs17576 of
MMP9 represent the targets for epigenetic regulation of
gene expression through posttranslational modifications
to histone proteins.
Association of SNP rs11225395 of theMMP8 gene with
IS risk was a major finding of our study. This
polymorphism contains functional motifs related to the
regulatory effects of transcription factors which, on the
one hand, regulate lipid and carbohydrate metabolism,
inflammation, and other pathways that drive the
progression of atherosclerosis; on the other hand, such
TFs are responsible for the regulation of neurogenesis
and other important biological processes in the brain. It is
reasonable to explore which gene regulatory networks
are capable to control the expression of the MMP8 gene
through the binding of TFs to a motif at SNP rs11225395.
NR3C1 is a transcription factor binding to glucocorticoid
response elements at targeted genes, affecting inflamma-
tory responses, cellular proliferation, and differentiation
in target tissues.44 HNF4A is a transcriptionally con-
trolled TF binding to DNA sites required for the
transcription of numerous genes including apolipopro-
tein CIII, a multifaceted protein involved in the
metabolism of triglyceride‐rich lipoproteins, associating
with hypertriglyceridemia and formation of atherosclero-
tic lesions and other pathological processes playing a role
in atherosclerosis.45 VDR is a nuclear receptor for
calcitriol, the active form of vitamin D3 which mediates
the action of this vitamin on cells. Study of Szeto et al46
provided strong evidence supporting an antiatherosclero-
tic role of the VDR signaling through the mechanism of
suppressing the activation of the local renin‐angiotensin
system in macrophages/leukocytes and within the
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atherosclerotic lesion. PLZF encodes a finger‐type tran-
scription factor, involved in physiological development,
proliferation, differentiation and apoptosis, processes
contributing to atherosclerosis.47 PPARA and PPARG
(peroxisome proliferator‐activated receptors) are mem-
bers of the nuclear receptor superfamily of ligand‐
inducible transcription factors, key regulators of perox-
isomal and mitochondrial β‐oxidation of fatty acids,
ketone body synthesis and systemic lipid metabolism and
also possess anti‐inflammatory activities.48 PPARA has
the potential to affect atherosclerosis via the regulation of
lipid metabolism and impact on the vascular inflamma-
tion.48 PPARG is also crucial for controlling gene
networks involved in glucose homeostasis.49 Peroxisome
proliferator‐activated receptors are expressed in multiple
brain regions especially in neurons.50 Notably, PPAR
agonists have well‐documented anti‐inflammatory and
neuroprotective roles in the central nervous system.50 We
also identified several transcription factors possessing to
mediate effects of the gene regulatory networks on
neuronal development and remodeling in the brain
through the control of MMP expression. For instance,
POU6F1 is required for proper dendrite specification and
patterning, as well as synapse development and function
in adult‐born neurons.51 Interestingly, POU6F1 promotes
transcription of neuronal genes and in cooperation with
transcription factors ASCL1 and MYT1L is capable to
reprogram fibroblasts and other somatic cells into
induced neuronal cells,52 making the gene regulatory
network operating by transcription factor POU6F1 an
attractive target to induce regeneration of the damaged
brain and restore its function after an ischemic attack. In
addition, the enrichment analysis for the gene set
including TFBS identified at SNP rs11225395 of MMP8
enabled finding biological processes which can be related
to disease pathogenesis through the regulation of lipid
metabolism, formation of atherosclerotic lesions and
cellular apoptosis as well as processes playing an
important role in ischemic injury of the brain and its
recovery after stroke attack.
4.3 | Study limitations
Our study has some limitations. First, many important
polymorphic genes for MMPs were not included in the
study. In particular, our study had no opportunity to
confirm robust associations of polymorphisms 1562 C/T
of MMP9 and − 1082A/G of MMP12 with the risk IS,
since these SNPs were not included in the study. Second,
the associations observed in our study need to be
confirmed in independent populations. Third, the roles
of interactions between MMPs and environmental factors
such as smoking, heavy drinking and lifestyle factors in
determining the risk of IS were not investigated in the
study. Although we have explored comprehensively the
functional potential of SNPs using bioinformatic meth-
ods, further studies are also required to investigate how
the polymorphisms influence the concentration of MMPs
in carotid arteries and the brain, thereby substantiating
their effects on disease pathogenesis.
5 | CONCLUSIONS
Despite the discrepancies observed between the conducted
studies polymorphic genes for MMPs are related with
susceptibility to IS, but their effects on disease risk are
ethnically dependent. This means that differences in the
genetic architecture between races and ethnicities as well
as population‐specific environmental exposures may influ-
ence the results of genetic studies of MMP genes in IS. A
joint contribution of MMPs to IS susceptibility has been
little studied, and so the findings of our study clearly
indicate that this class of genes deserves special attention as
potential genetic factors influencing the multistep mechan-
isms of cerebrovascular disease. The pleiotropic biological
effects of MMPs on various pathogenetic stages of the
cerebrovascular disease may include the involvement of
MMPs in the formation of atherosclerosis, atherothrombo-
sis of cerebral vessels and the contribution of the enzymes
to brain damage and its subsequent recovery. Complex
interactions between various MMPs as well as with the
known disease susceptibility genes demonstrate that MMPs
may be collectively involved in the polygenic mechanisms
of cerebrovascular disease. Further studies of independent
ethnic populations are needed to substantiate the role of
MMPs genes in the pathogenesis of IS and to investigate
the mechanisms by which the polymorphisms influence
the concentration of these proteins in carotid arteries and
the brain. Moreover, genetic studies focusing on a wider
spectrum of polymorphic genes encoding MMPs, their
gene‐gene, and gene‐environment interactions can provide
a better understanding the molecular mechanisms by
which the enzymes are involved in the complex patho-
physiology of cerebrovascular disease and end up in the
discovery of novel drug targets for treatment and preven-
tion of the disease.
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